PHI-101

Modify Date: 2024-01-21 11:37:27

PHI-101 Structure
PHI-101 structure
Common Name PHI-101
CAS Number 2127107-15-5 Molecular Weight 386.44
Density N/A Boiling Point N/A
Molecular Formula C19H19FN4O2S Melting Point N/A
MSDS N/A Flash Point N/A

 Use of PHI-101


PHI-101 is an orally active FLT3 inhibitor that overcomes resistance to multiple drug-resistant mutations. PHI-101 potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. PHI-101 has potential for research in relapsed or refractory acute myeloid leukemia (AML)[1].

 Names

Name PHI-101

 PHI-101 Biological Activity

Description PHI-101 is an orally active FLT3 inhibitor that overcomes resistance to multiple drug-resistant mutations. PHI-101 potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. PHI-101 has potential for research in relapsed or refractory acute myeloid leukemia (AML)[1].
Related Catalog
References

[1]. Nam K Y, et al. PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia[J]. Blood, 2020, 136: 28.

 Chemical & Physical Properties

Molecular Formula C19H19FN4O2S
Molecular Weight 386.44
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.